EUVIMEDEUVIMED entdecken
Multizentrische Studie

The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET/CT for the pathological upgrade in prostate cancer: a multicenter study

Jian Xu, Haisong Chen, Lixuan Chen, Tiancheng Li, Heng Lin, Shuying Bian, Qi Lin, Yuandi Zhuang, Yingnan Xue, Yunjun Yang, Xinhui Su, Fei Yao iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07311-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Jian Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Multiparametric Magnetic Resonance Imaging, Niacinamide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: State Key Laboratory of Microwave and Digital Communication, Wenzhou Major Program of Science and Technology Innovation, Natural Science Research Project of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to develop a predictive model that integrates parameters derived from preoperative multiparametric magnetic resonance imaging (mpMRI) and [18F]PSMA-1007 PET/CT for reliably predicting pathological upgrading from systematic biopsy (SB) to radical prostatectomy (RP) specimens. METHODS: We ultimately retrospectively analyzed 163 patients with biopsy-confirmed localized prostate cancer (PCa) who underwent preoperative mpMRI and [18F]PSMA-1007 PET/CT scans between January 2019 and June 2022. Clinical and imaging characteristics were compared between patients with and without pathological upgrading. Predictive factors for pathological upgrading were evaluated through univariate and multivariable analyses. Predictive models were constructed based on the identified parameters. Receiver operating characteristic (ROC) curves were utilized to determine optimal cutoff values and to evaluate model performance. Additionally, patients from two external centers were selected as a validation cohort. RESULTS: A total of 55 (33.7%) cases experienced pathological upgrading. Multivariate analysis revealed that ADCmean - ADCmin (P = 0.035); SUVmax (P = 0.003); highest tumor grade at SB, ISUP grade group (ISUP GG) 1 vs. 2 (P = 0.001), ISUP GG 1 vs. 3 (P < 0.001), ISUP GG 1 vs. 4 (P < 0.001); and multifocality on [18F]PSMA-1007 PET/CT (P = 0.007) were independent predictors for pathological upgrading. The combined model achieved an area under the curve (AUC) of 0.803 (95% CI: 0.734 to 0.861), indicating robust discriminative power. External validation confirmed the model's reliability and predictive ability. CONCLUSION: Our predictive model, integrating mpMRI and [18F]PSMA-1007 PET/CT parameters, effectively forecasts pathological upgrading in PCa, allowing for more precise treatment risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyMultiparametric Magnetic Resonance ImagingNiacinamideOligopeptidesHumansMaleMiddle AgedRetrospective StudiesAgedFluorine RadioisotopesPredictive Value of Tests

Stichwörter der Autor:innen

MpMRIPathological upgradingProstate cancerSystematic biopsy[18F]PSMA-1007 PET/CT

Substanzen

PSMA-1007NiacinamideOligopeptidesFluorine Radioisotopes

Autor:innen und Institutionen

  • The Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
  • The Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
  • The Departments of Nuclear Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
  • The Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
  • The Departments of Nuclear Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, China. suxinhui@zju.edu.cn.

ORCID-Profile: Fei Yao

Förderung

  • State Key Laboratory of Microwave and Digital Communication
  • Wenzhou Major Program of Science and Technology Innovation
  • Natural Science Research Project of Guizhou Province
  • Science and Technology Plan Project of Wenzhou Municipality

Zitieren

APA

Xu, J., Chen, H., Chen, L., Li, T., Lin, H., Bian, S., Lin, Q., Zhuang, Y., Xue, Y., Yang, Y., Su, X., & Yao, F. (2025). The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET/CT for the pathological upgrade in prostate cancer: a multicenter study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07311-1

Vancouver

Xu J, Chen H, Chen L, Li T, Lin H, Bian S, et al. The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET/CT for the pathological upgrade in prostate cancer: a multicenter study. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07311-1

BibTeX
@article{Xu2025,
  author = {Xu, Jian and Chen, Haisong and Chen, Lixuan and Li, Tiancheng and Lin, Heng and Bian, Shuying and Lin, Qi and Zhuang, Yuandi and Xue, Yingnan and Yang, Yunjun and Su, Xinhui and Yao, Fei},
  title = {The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET/CT for the pathological upgrade in prostate cancer: a multicenter study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07311-1}
}
Kostenlos starten →